693 matches
-
2006; 355: 11-20. 4. Boige V, Pignon J, Saint-Aubert B et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone în adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol (Meeting Abstracts) 2007; 25: 4510. 5. MacDonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730. 6. MacDonald J
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820. 9. Wagner AD, Grothe W, Haerting J et al. Chemotherapy în advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-2909. 10. Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
2903-2909. 10. Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997. 11. Dank M, Zaluski J, Barone C et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil în chemotherapy naive patients with advanced adenocarcinoma of the stomach
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
13. Kang Y, Kang WK, Shin DB et al. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy în patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results. J Clin Oncol (Meeting Abstracts) 2006; 24: LBA4018. 14. Al-Batran S-E, Hartmann JT, Probst S et al. Phase III trial în metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Clin Oncol (Meeting Abstracts) 2006; 24: LBA4018. 14. Al-Batran S-E, Hartmann JT, Probst S et al. Phase III trial în metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26: 1435-1442. 15. Okines AFC NA, McCloud P, Kang Y-K, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials comparing capecitabine with 5-fluorouracil (5-FU) în advanced oesophago-gastric cancer. Annals of Oncology 2008; 19 (Suppl 8): viii169 (Abstr 513PD
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
1. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality în Europe în 2006. Ann Oncol 2007; 18: 581-592. 2. Gold EB, Goldin SB. Epidemiology of and risk factors for pancreatic cancer. Surg Oncol Clin N Am 1998; 7: 67-91. 3. IchiKawa T, Haradome H. Hachiya et al. Pancreatic ductal adenocarcinoma: preoperative assessment with helical CT versus dynamic MR imaging. Radiology 1997; 202: 655-662. 4. Neoptolemos JP, Stocken DD, Friess H et al. A randomized
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
trials for pancreatic cancer. Br J Cancer 2005; 92: 1372-1381. 7. Huguet F, Andre T, Hammel P et al. Impact of chemoradiotherapy after disease control with chemotherapy în locally advanced pancreatic adenocarcinoma în GERCOR phase II and III studies. J Clin Oncol 2007; 25: 326-331. 8. Burris HA, Moore MJ, Andersen J et al. Improvements în survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413. 9
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
II and III studies. J Clin Oncol 2007; 25: 326-331. 8. Burris HA, Moore MJ, Andersen J et al. Improvements în survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413. 9. Cunningham D, Chau I, Stocken C et al. Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine în patients with advanced pancreatic cancer. Eur J Cancer 2005; 3 (4 Suppl): 312. 10. Hermann R
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
10. Hermann R, Bodoky G, Ruhstaller T et al. Gemcitabine plus capecitabine versus gemcitabine alone în advanced pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007; 25: 2212-2217. 11. Heinemann V, Boeck S, Hinke A et al. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied în advanced pancreatic cancer. BMC Cancer 2008; 28: 8-82. 12. Moore MJ, Goldstein D, Hamm
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
2008; 28: 8-82. 12. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone în patients with advanced pancreatic cancer: a phase III trial of the Național Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966. 13. Rykowski JJ, Hilgier M. Efficacy of neurolytic celiac plexus block în varying locations of pancreatic cancer: influence on pain relief. Anesthesiology 2000; 92: 347-354. Carcinomul hepatocelular Recomandări ESMO pentru diagnostic, tratament și urmărire S. Jelic
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
GJ. Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology 2000; 31: 1019-1021. 5. Leung TWT, Patt YZ, Lau W-Y et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999; 5: 1676-1681. 6. Bergsland EK, Venook AP. Hepatocellular carcinoma. Curr Opin Oncol 2000; 12: 357-361. 7. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma în the United States. N Engl J Med 1999; 340: 745-750. 8
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351. 6. Benson A, Schrag D, Somerfield M et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 1-12. 7. Twelves C, Wong A, Nowacki M et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-2704. 8. Van Cutsem E, Tejpar S, Verslype C, Laurent S. Challenges
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
370: 2020-2029. 10. Sargent DJ, Patiyil S, Yothers G et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20 898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 2007; 25: 4569-4574. 11. Pfister D, Benson A, Somerfield M. Surveillance strategies after curative treatment of colorectal cancer. New Engl J Med 2004; 350: 2375-2382. 12. Desch C, Benson A, Somerfield M et al. Colorectal cancer surveillance: 2005 update
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
M. Surveillance strategies after curative treatment of colorectal cancer. New Engl J Med 2004; 350: 2375-2382. 12. Desch C, Benson A, Somerfield M et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology Practise Guideline. J Clin Oncol. 23. 2005; 8512-8519 Cancerul rectal Recomandări ESMO pentru diagnostic,tratament și monitorizare B. Glimelius*1) amp; J. Oliveira*2) Din partea Grupului de Lucru ESMO pentru Ghiduri Terapeutice*) *1) Department of Oncology, Radiology and Clinical Immunology, University Hospital, Uppsala and
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740. 7. Folkesson J, Birgisson H, Pa° hlman L et al. Swedish Rectal Cancer Trial: Long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005; 23: 5644-5650. 8. Bipat S, Glas AS, Slors FJ et al. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging-a metaanalysis. Radiology 2004; 232: 773-783. 9. Sebag-Montefiore-D for the NCRI
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
for rectal cancer. Br J Surg 2006; 93: 1215-1223. 11. Collette L, Bosset JF, den Dulk M et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? J Clin Oncol 2007; 25: 4379-4386. 12. Radu C, Berglund A° Pa° hlman L, Glimelius B. Short course preoperative radiotherapy with delayed surgery în rectal cancer - a retrospective study. Radiother Oncol 2008; 87: 343-349. Cancerul colorectal avansat: Recomandări ESMO pentru diagnostic,tratament
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
oxaliplatin as first-line treatment în advanced colorectal cancer. J ClinOncol 2000; 18: 2938-2947. 3. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX 6 or the reverse sequence în advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237. 4. Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised phase III trials. Br J Cancer 2004; 90: 1190-1197
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
irinotecan refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345. 11. Tournigand C, Cervantes A, Figer A et al. FOLFOX 4 or FOLFOX 7 with oxaliplatin stop-and-go în advanced colorectal cancer. Optimox 1, a randomised GERCOR study. J Clin Oncol 2006; 24: 394-400. 12. Cassidy Clarke S, Diaz-Rubio E et al. Randomized phase III study of capecitabina plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-2012
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
randomised GERCOR study. J Clin Oncol 2006; 24: 394-400. 12. Cassidy Clarke S, Diaz-Rubio E et al. Randomized phase III study of capecitabina plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-2012. 13. Arkenau H-T, Arnold D, Cassidy J et al. Efficacy of oxaliplatin plus capecitabina or infusional fluorouracil/leucovorin în patients with metastatic colorectal cancer: a pooled analysis of randomized trials. Clin Oncol 2008; 26: 5910-5917
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-2012. 13. Arkenau H-T, Arnold D, Cassidy J et al. Efficacy of oxaliplatin plus capecitabina or infusional fluorouracil/leucovorin în patients with metastatic colorectal cancer: a pooled analysis of randomized trials. Clin Oncol 2008; 26: 5910-5917. 14. Saltz LB, Clarke S, Di'az-Rubio E et al. Bevacizumab în combination with oxaliplatin-based chemotherapy as first-line therapy în metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019. 15. Cunningham
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
a pooled analysis of randomized trials. Clin Oncol 2008; 26: 5910-5917. 14. Saltz LB, Clarke S, Di'az-Rubio E et al. Bevacizumab în combination with oxaliplatin-based chemotherapy as first-line therapy în metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019. 15. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan în irinotecan refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345. 16. Jonker D, O'Callaghan C, Karapetis C
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
N Engl J Med 2007; 357: 2040-2048. 17. Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive carealone în patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664. 18. Amado RG, Wolf M, Peeters M, Van Cutsem E et al. Wild-type KRAS is required for panitumumab efficacy în patients with metastatic colorectal cancer. J ClinOncol 2008; 26: 16261634. Tumorile stromale gastrointestinale Recomandările ESMO pentru
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Glabbeke, Brussels, Belgium Allan Van Oosterom, Leuven, Belgium Jaap Verweij, Rotterdam, Netherlands Eva Wardelmann, Bonn, Germany John Zalcberg, Melbourne, Australia Bibliografie 1. Benjamin RS, Choi H, Macapinlac HA et al. We should desist using RECIST, at least în GIST. J Clin Oncol 2007; 25: 1760-1764. 2. Blanke CD, Demetri GD, von Mehren M et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumours expressing KIT. J
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Oncol 2007; 25: 1760-1764. 2. Blanke CD, Demetri GD, von Mehren M et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumours expressing KIT. J Clin Oncol 2008; 26: 620-625. 3. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels în patients with unresectable or metastatic gastrointestinal stromal tumours expressing the kit receptor tyrosine kinase
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
26: 620-625. 3. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels în patients with unresectable or metastatic gastrointestinal stromal tumours expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26: 626-632. 4. Blay JY, Le Cesne A, Ray-Coquard I et al. Prospective multicentric randomized phase III study of imatinib în patients with advanced gastrointestinal stromal tumours comparing interruption versus continuation of treatment beyond 1 year: the French
EUR-Lex () [Corola-website/Law/227406_a_228735]